RESUMO
Background: Immunogenicity of Streptokinase, as a thrombolytic drug, has limited its clinical use. Elimination of the amino acid residues that are responsible for immunogenicity while don't affect the bioactivity of streptokinase is worthy. Recently, we modified the streptokinase through the elimination of 42 amino acids from its' C-terminal and assessed its bioactivity in vitro. In this study, bioactivity of the mutated-streptokinase determined and compared with those of commercially available streptokinase [Heberkinase] in rabbits with induced blood clot
Materials and Methods: Recombinant mutated streptokinase was purified and its lipopolysaccharide contained remove and evaluated by LAL test. Thrombolytic activity of drug was evaluated by rabbit jugular vein as in vivo thrombosis model. The thrombolytic property of the drug was evaluated with determining of D-dimer in plasma
Results: The results showed in vivo bioactivity of both truncated and commercial streptokinase [p<0.05]. This study showed an important influence of the 42 amino acids of C-terminal in bioactivity of the streptokinase
Conclusion: Clinical use of the r-streptokinase requires more modification to restore its' activity in vivo. This product may be a promising choice for clinical use after confirmation of its stability and non-immunogenicity